In conclusion, we present a case of a patient with advanced CD74-ROS1 fusion NSCLC who acquired resistance to lorlatinib concurrent with developing a novel RUFY1-RET fusion, with both oncogenic fusion events identified on RNA NGS only. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.